Thailand Reaffirms Medical-Only Cannabis Policy as Industry Looks Toward Research and Growth

Thailand is reinforcing its medical-focused approach to cannabis, with government leaders emphasizing public health, stronger enforcement and the development of higher-value cannabis research.

On October 22, 2026, Prime Minister and Minister of Interior Anutin Charnvirakul chaired a meeting of the country's Narcotics Control Board, where cannabis policy was among the issues discussed.

According to an official Thai government announcement, the prime minister emphasized that cannabis should be used for medical purposes, including modern and traditional medicine, rather than recreational consumption.

The announcement reflects Thailand's continuing effort to establish clearer boundaries for an industry that has experienced significant regulatory changes in recent years.

Thailand's Changing Cannabis Policy

Thailand attracted international attention when it removed cannabis from its narcotics list in 2022, creating a rapidly expanding commercial market.

Following the expansion of Thailand's cannabis market, authorities introduced tighter regulations that placed greater emphasis on medical use, public health and regulatory oversight.

In June 2025, Thailand introduced restrictions focusing cannabis access on medical purposes. Those measures included prescription requirements, restrictions on sales, and prohibitions on cannabis advertising and online sales.

The government's October 2026 announcement reinforces that medical-focused direction rather than introducing an entirely new nationwide legalization framework.

Greater Emphasis on Research and Medical Applications

Alongside tighter controls, Thai officials have emphasized the potential value of cannabis in medical research and development.

The government says it supports research that could lead to higher-value cannabis applications.

For businesses operating in cultivation, pharmaceutical development and medical products, that approach may create opportunities tied to regulatory compliance, product quality and scientific development.

However, the government's support for medical research should not be interpreted as an announcement of new export permissions or unrestricted international cannabis trade.

Companies must still comply with applicable Thai regulations and the laws of any destination market.

Enforcement Remains a Government Priority

Thailand's policy also places considerable emphasis on preventing cannabis misuse, particularly among children and young people.

Earlier in 2026, Thai authorities reported inspections of more than 1,200 cannabis establishments as part of expanded regulatory oversight.

The October Narcotics Control Board meeting addressed broader drug enforcement priorities, including illegal trafficking networks, cross-border cooperation and prevention programs.

These developments indicate that the government intends to pursue medical cannabis development alongside stricter enforcement of drug-related regulations.

What It Means for the International Cannabis Industry

Thailand remains an important country to watch because its regulatory direction could influence investment, business planning and medical cannabis development in Southeast Asia.

For international companies, the distinction between medical cannabis activity and recreational sales is especially important.

Businesses considering partnerships, cultivation investments or research projects will need to evaluate licensing requirements and the country's evolving regulatory environment.

Thailand's latest announcement suggests that future industry opportunities will increasingly depend on medical applications, regulatory compliance and research rather than broad recreational retail expansion.